OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research note published on Tuesday. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reaffirmed a buy rating and issued a $4.25 price target on shares of OncoCyte in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, OncoCyte presently has an average rating of Hold and an average target price of $4.06.

OncoCyte Stock Performance

OCX opened at $3.19 on Tuesday. The business has a fifty day moving average of $3.12 and a 200 day moving average of $2.93. OncoCyte has a 52-week low of $2.08 and a 52-week high of $4.34.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The company had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. On average, analysts expect that OncoCyte will post -2.58 EPS for the current fiscal year.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.